Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.35 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3523 | 0.92 | SMN1; SMN2 (0.37) | POLBALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL2879833 | 0.92 | SMN1; SMN2 (0.41) | POLBALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL2505 | 0.90 | SMN1; SMN2 (0.36) | POLBALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL1709463 | 0.87 | OPRM1 (0.48) | POLBALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL1972216 | 0.87 | TSHR (0.40) | POLBALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL31147335 | 0.87 | ALDH1A1 (0.39) | POLBALDH1A1TSHRKMT2ASMN1; SMN2 | |
| SCHEMBL15166914 | 0.86 | POLB (0.38) | POLBALDH1A1TSHRMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1283011 | 0.86 | OPRM1 (0.47) | POLBALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL1709447 | 0.84 | OPRM1 (0.35) | ALDH1A1TSHRKMT2AOPRM1SMN1; SMN2 | |
| SCHEMBL1292327 | 0.83 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2AOPRM1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | claimed |
| US-20260146043-A1 | CRYSTALLINE FORMS OF PYRIMIDINO DIAZEPINE DERIVATIVE | CYCLACEL PHARMACEUTICALS INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12583858-B2 | TDO2 inhibitors | GENENTECH, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12570660-B2 | Process for the preparation of a pyrimidino-diazepine derivative | CYCLACEL PHARMACEUTICALS, INC (GB) | 2026-03-10 | — | — | US | disclosed |
| US-12534466-B2 | Crystalline forms of pyrimidino diazepine derivative | CYCLACEL PHARMACEUTICALS INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-12479858-B2 | Macrocyclic compounds as sting agonists and methods and uses thereof | LUPIN LIMITED (IN) | 2025-11-25 | — | — | US | disclosed |
| US-20250214995-A1 | CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-07-03 | — | — | US | disclosed |
| CN-115175905-B | ZESTE enhancer homolog 2 inhibitors and uses thereof | 西藏海思科制药有限公司 | 2025-03-25 | — | — | CN | disclosed |
| US-20250092027-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2025-03-20 | — | — | US | disclosed |
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | disclosed |
| US-5980896-A | Antibodies reactive with human carcinomas | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-11-09 | — | — | US | disclosed |
| US-5869045-A | POLYPEPTIDE COMPRISING ANTIGEN-BINDING REGION OF MONOCLONAL ANTIBODY PRODUCED BY SPECIFIED HYBRIDOMA | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-02-09 | — | — | US | disclosed |
| US-5708146-A | ANTIBODIES AND DRUGS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| US-5622929-A | ANTHRACYCLINE ANTIBIOTIC; ANTITUMOR AGENT BINDS WITH A TARGET CELL | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5606017-A | ANTITUMOR AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-02-25 | — | — | US | disclosed |
| US-5384331-A | Ketamine analogues for treatment of thrombocytopenia | GENENTECH, INC. (US) | 1995-01-24 | — | — | US | disclosed |
| EP-0623343-A1 | Ketamine analogues for the treatment of thrombocytopenia | GENENTECH, INC. (US) | 1994-11-09 | — | — | EP | disclosed |
| US-5250732-A | Influence replication, differentiation or maturation of platelet progenitor cells | GENENTECH, INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0554708-A1 | Thioether conjugates | Bristol-Myers Squibb Company (US) | 1993-08-11 | — | — | EP | disclosed |
| US-4236018-A | Process for preparing cyclopropane carboxylic acids | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570660-B2 | Process for the preparation of a pyrimidino-diazepine derivative | AZI2, TFPI, GTF2I | POLB 951/4885ALDH1A1 1477/4885TSHR 1771/4885 |
| US-12479858-B2 | Macrocyclic compounds as sting agonists and methods and uses thereof | STING1, CGAS, MAVS | POLB 930/4885ALDH1A1 4861/4885TSHR 1898/4885 |
| US-12583858-B2 | TDO2 inhibitors | TDO2, IDO2, TPH2 | POLB 3565/4885ALDH1A1 1758/4885TSHR 330/4885 |
| US-20250092027-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | POLB 1146/4885ALDH1A1 1361/4885TSHR 4016/4885 |
| US-20260146043-A1 | CRYSTALLINE FORMS OF PYRIMIDINO DIAZEPINE DERIVATIVE | CTNND1, CCNC, SFN | POLB 1638/4885ALDH1A1 4484/4885TSHR 3531/4885 |
| US-12534466-B2 | Crystalline forms of pyrimidino diazepine derivative | PLK1, BUB1, CDC25C | POLB 70/4885ALDH1A1 3362/4885TSHR 4609/4885 |
| US-20250214995-A1 | CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, SDHA | POLB 213/4885ALDH1A1 429/4885TSHR 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.